BioRestorative Therapies, Inc. (BRTX)
NASDAQ: BRTX · Real-Time Price · USD
1.660
+0.040 (2.47%)
At close: Oct 8, 2025, 4:00 PM EDT
1.710
+0.050 (3.01%)
After-hours: Oct 8, 2025, 6:14 PM EDT
BioRestorative Therapies Revenue
BioRestorative Therapies had revenue of $303.30K in the quarter ending June 30, 2025, with 240.40% growth. This brings the company's revenue in the last twelve months to $605.20K, up 247.62% year-over-year. In the year 2024, BioRestorative Therapies had annual revenue of $401.00K with 175.03% growth.
Revenue (ttm)
$605.20K
Revenue Growth
+247.62%
P/S Ratio
22.32
Revenue / Employee
$55,018
Employees
11
Market Cap
13.24M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 401.00K | 255.20K | 175.03% |
Dec 31, 2023 | 145.80K | 26.00K | 21.70% |
Dec 31, 2022 | 119.80K | 73.80K | 160.43% |
Dec 31, 2021 | 46.00K | -31.00K | -40.26% |
Dec 31, 2020 | 77.00K | -53.00K | -40.77% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
BRTX News
- 1 day ago - BioRestorative CEO Lance Alstodt Interviewed on “The Big Biz Show” - GlobeNewsWire
- 2 days ago - BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market - GlobeNewsWire
- 2 months ago - BioRestorative Therapies, Inc. (BRTX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025 - GlobeNewsWire
- 4 months ago - BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates - GlobeNewsWire
- 4 months ago - BioRestorative Announces Share Repurchase Program - GlobeNewsWire
- 4 months ago - BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease - GlobeNewsWire
- 4 months ago - BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025 - GlobeNewsWire